Previous 10 | Next 10 |
2024-01-03 06:16:20 ET Dr. Reddy's Laboratories ( NYSE: RDY ) on Wednesday announced a deal to acquire a women's health and dietary supplements portfolio of brands from Amyris ( OTC:AMRSQ ) as part of the latter's Chapter 11 sales process. Terms of the deal were not disc...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced that it has acquired MenoLabs ® business, a leading women’s health and dietary supplement branded portfolio fr...
2023-12-29 14:52:48 ET More on Dr. Reddy's Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements Dr Reddy's Laboratories Ltd (RDY) Q2 2024 Earnings Call Transcript Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investme...
2023-12-24 02:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-14 12:30:25 ET The Biden administration on Thursday named 48 Medicare Part B drugs that could be subject to inflation penalties for Q1 2024, including products from the likes of AbbVie ( NYSE: ABBV ), Amgen ( NASDAQ: AMGN ), and Pfizer ( NYSE: PFE ). Drug...
Company also secures ‘Gold Medal’ status from global sustainability ratings agency, EcoVadis In a first for Indian pharma, Dr. Reddy’s is featured in the Dow Jones Sustainability World Index for 2023 Company retains its place in the Dow Jones Sustainability ...
2023-12-11 12:23:16 ET More on Dr. Reddy's Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements Dr Reddy's Laboratories Ltd (RDY) Q2 2024 Earnings Call Transcript Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investme...
2023-12-06 07:40:06 ET More on Coya Therapeutics Historical earnings data for Coya Therapeutics Financial information for Coya Therapeutics For further details see: Dr Reddy's licenses Coya ALS candidate in exclusive deal
Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be responsible for development, including the conduct of the Phase 2 clinical trial and fo...
2023-12-01 13:40:47 ET More on Amarin, Amneal, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information mentioned in this release is based on consolidated financial statements un...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-03 22:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...